All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
TOKYO – Exelixis Inc. and Takeda Pharmaceutical Co. Ltd. reached an exclusive licensing agreement for the commercialization and further clinical development in Japan of oncology drug cabozantinib. The deal grants Takeda exclusive commercial and further clinical development rights in Japan for cabozantinib.